FDA Tentatively Identifies 30 PACHA Vape SKUs for Non-Priority Enforcement List

Executive summary

The U.S. Food and Drug Administration has tentatively identified 30 PACHA-branded vape SKUs for inclusion on a public-facing non-priority enforcement list, according to Charlie’s Holdings. The products, which have submitted premarket tobacco product applications (PMTAs), are not currently authorized but are not expected to be a primary enforcement target under FDA’s updated guidance. This development underscores the agency’s evolving enforcement strategy amid a growing backlog of PMTA submissions and increasing pressure to balance regulatory rigor with market stability.

Regulatory signal: The FDA’s non-priority designation indicates a strategic de-escalation of enforcement for products with pending PMTAs, signaling long-term tolerance for market presence during review.

What happened

On June 23, 2026, the FDA notified Charlie’s Holdings that 30 PACHA vape SKUs—each with submitted PMTAs—had been tentatively identified for inclusion on a forthcoming public list. The list, part of the FDA’s May 2026 enforcement guidance, is intended to clarify which unauthorized products the agency does not plan to prioritize for enforcement actions. The products remain unauthorized under the Federal Food, Drug, and Cosmetic Act, but the tentative inclusion suggests the FDA views them as low enforcement risk due to their PMTA status and compliance efforts.

Charlie’s Holdings disclosed the update alongside its second-quarter financial results, reporting $3.8 million in revenue—a 116% year-over-year increase. The company attributed the growth to expanded distribution and continued consumer demand for flavored vape products, despite regulatory uncertainty.

Why it matters

This move marks a significant shift in the FDA’s enforcement posture. Rather than treating all unauthorized products as equal enforcement targets, the agency is now categorizing them based on PMTA submission status. Products with active PMTAs are being placed in a lower enforcement tier, reflecting a recognition that many brands are attempting to comply with the law, even if the review process is delayed.

The distinction between authorized and unauthorized products remains legally binding, but the non-priority designation reduces the immediate risk of seizures, fines, or market removal for these 30 SKUs. This provides temporary stability for retailers and brands navigating a complex regulatory landscape, particularly in states with strict enforcement regimes.

Market impact

The tentative inclusion on the non-priority list offers short-term relief for PACHA’s distribution network and retail partners. With 30 SKUs remaining on shelves without immediate enforcement risk, retailers can continue sales with reduced legal exposure. This stability may encourage continued investment in flavored vape products, which remain a key driver of consumer preference and brand loyalty.

For smaller brands with PMTAs pending, the FDA’s approach sets a precedent: submission alone may provide a buffer against aggressive enforcement, even if approval is years away. This could incentivize more brands to file PMTAs, even with low approval odds, to gain de facto market protection.

However, the move also risks normalizing the sale of unauthorized products, potentially undermining the PMTA framework’s credibility. If market participants interpret the non-priority list as a loophole, it could erode compliance incentives and delay the exit of non-compliant products.

Market operator insight: Brands with PMTAs in progress now have a clear path to operational continuity, but long-term success depends on final approval—not regulatory tolerance.

Regulatory impact

The FDA’s public enforcement prioritization framework represents a pragmatic response to a backlog of over 1,200 PMTA submissions. By identifying products with pending applications as non-priority, the agency is reallocating resources to focus on products with no PMTA submission, unapproved modifications, or high youth appeal.

This tiered enforcement model introduces a new layer of regulatory transparency. The upcoming public list will serve as a de facto compliance map, allowing stakeholders to assess risk levels based on FDA’s own criteria. However, the list’s tentative nature means it is subject to change, and final decisions may not be made until after the PMTA review process concludes.

Who is affected

• Brands with pending PMTAs: Gain temporary market protection and reduced enforcement risk.
• Regulated retailers: Can continue selling these SKUs with lower legal exposure, though compliance monitoring remains essential.
• State and local regulators: May adjust enforcement strategies in alignment with federal guidance, though some jurisdictions may maintain stricter standards.
• Consumers: Benefit from continued product availability, though access to unreviewed products remains a public health concern.
• Compliance teams: Must track PMTA status and enforcement list updates to avoid exposure to enforcement actions.

Dawsen Take

The FDA’s non-priority enforcement list is not a backdoor approval, but a strategic pause in enforcement for products already in the system. It reflects a growing acknowledgment that the PMTA process, while necessary, cannot be the sole enforcement tool when thousands of applications remain unresolved. The move signals that compliance effort—specifically, PMTA submission—now carries tangible market value, even in the absence of approval.

For the vaping industry, this is a moment of cautious optimism. The regulatory environment remains complex and uncertain, but the FDA is beginning to distinguish between good-faith compliance and non-compliance. This distinction is critical for market stability and long-term brand viability.

What to watch

Key developments to monitor include:

• The finalization and public release of the non-priority enforcement list, expected by Q4 2026.
• Whether the FDA extends the non-priority status to additional PMTA-submitted products.
• State-level responses—some states may adopt the federal guidance, while others may maintain stricter enforcement.
• Long-term PMTA approval rates and timelines, which will determine whether the non-priority designation translates into lasting market access.

For more daily vaping news, check out dawsenai.com.

Original source: 2FIRSTS | Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List